Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial
- 13 May 2020
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 226, 49-59
- https://doi.org/10.1016/j.ahj.2020.05.002
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndromeCritical Care, 2017
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of AmericaCirculation, 2017
- The Emergence of the Randomized, Controlled TrialThe New England Journal of Medicine, 2016
- Registry-based randomized clinical trials—a new clinical trial paradigmNature Reviews Cardiology, 2015
- Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on All-Cause Mortality, Cardiovascular Deaths, and Cardiovascular Events in Patients With Diabetes MellitusJAMA Internal Medicine, 2014
- The Randomized Registry Trial — The Next Disruptive Technology in Clinical Research?The New England Journal of Medicine, 2013
- Thrombus Aspiration during ST-Segment Elevation Myocardial InfarctionThe New England Journal of Medicine, 2013
- ACE2: from vasopeptidase to SARS virus receptorTrends in Pharmacological Sciences, 2004
- ACE Inhibition Versus Angiotensin Type 1 Receptor AntagonismHypertension, 2002
- Repeated assessment of results in clinical trials of cancer treatmentThe British Journal of Radiology, 1971